Company Filing History:
Years Active: 2024-2025
Title: Surjit Bhimarao Dixit: Innovator in Immunoglobulin Engineering
Introduction
Surjit Bhimarao Dixit is a notable inventor based in Richmond, CA, recognized for his contributions to the field of immunoglobulin engineering. With a total of five patents to his name, Dixit has made significant advancements in the development of engineered immunoglobulin heavy chain-light chain pairs.
Latest Patents
Dixit's latest patents include innovative technologies that focus on engineered immunoglobulin heavy chain-light chain pairs and their applications. One of his inventions provides heterodimer pairs that consist of a first and a second heterodimer, each comprising an immunoglobulin heavy chain or fragment and an immunoglobulin light chain or fragment. These heterodimers can include amino acid modifications in the C and/or V domains, which enhance the preferential pairing between heavy and light chains. This technology allows for specific pairing when co-expressed in cells, optimizing the functionality of the immunoglobulins.
Another significant patent by Dixit involves modified antigen binding polypeptide constructs, which similarly utilize heterodimer pairs to achieve preferential pairing between heavy and light chains. This innovation aims to improve the efficiency and specificity of immunoglobulin interactions, which is crucial for therapeutic applications.
Career Highlights
Throughout his career, Surjit Bhimarao Dixit has worked with prominent companies in the biotechnology sector, including Zymeworks Inc. and Zymeworks Bc Inc. His work in these organizations has contributed to the advancement of immunotherapy and related fields.
Collaborations
Dixit has collaborated with several professionals in his field, including Mario Sanches and Thomas Spreter Von Kreudenstein. These collaborations have fostered innovation and development in immunoglobulin research.
Conclusion
Surjit Bhimarao Dixit is a distinguished inventor whose work in immunoglobulin engineering has led to significant advancements in the field. His patents reflect a commitment to enhancing the specificity and efficiency of immunoglobulin interactions, paving the way for future innovations in therapeutic applications.